专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

US20110008891A1 PARTIAL PEPTIDE OF LACRITIN 有权
标题翻译： LACRITIN的部分肽
公开(公告)号：US20110008891A1
公开(公告)日：2011-01-13
申请号：US12922084
申请日：2009-03-19
申请人： Takeshi Nakajima , Mitsuyoshi Azuma
发明人： Takeshi Nakajima , Mitsuyoshi Azuma
IPC分类号： C12N5/071 , C07K14/47
CPC分类号： C07K14/475 , A61K9/0048 , A61K38/00
摘要： The invention provides a polypeptide comprising the amino acid sequence of SEQ ID NO: 1, which is a particular partial sequence of lacritin, and having an amino acid length of not more than 70 residues. The polypeptide of the invention can promote adhesion between a cell and an extracellular matrix, and can promote tear fluid secretion from lacrimal gland acinar cells.
摘要翻译：本发明提供了包含SEQ ID NO：1的氨基酸序列的多肽，其是lacritin的特定部分序列，并且具有不超过70个残基的氨基酸长度。本发明的多肽可以促进细胞和细胞外基质之间的粘附，并且可以促进泪腺腺泡细胞的泪液分泌。

22. 发明申请

US20090247543A1 GATIFLOXACIN-CONTAINING AQUEOUS LIQUID PREPARATION 审中-公开
标题翻译：含有GATIFLOXACIN的含水液体制剂
公开(公告)号：US20090247543A1
公开(公告)日：2009-10-01
申请号：US12415242
申请日：2009-03-31
申请人： Shirou SAWA
发明人： Shirou SAWA
IPC分类号： A61K31/497 , A61P27/02
CPC分类号： A61K31/497 , A61K9/0048 , A61K31/496 , A61K45/06 , A61K47/36 , A61K2300/00
摘要： There is provided an aqueous liquid preparation comprising Gatifloxacin or a pharmacologically acceptable salt thereof or a hydrate thereof, phosphoric acid or a salt thereof, and xanthan gum, wherein a pH thereof is 5.5 or more and less than 7.0. The aqueous liquid preparation has improved intraocular penetration of Gatifloxacin. Further, the formation of a precipitate during storage at a lower temperature and at the time of freezing and thawing of the aqueous liquid preparation is suppressed by incorporating at least one of the ingredient selected from the group consisting of nicotinamide, caffeine, methylglucamine, methyl parahydroxybenzoate and a salt thereof into the aqueous liquid preparation.
摘要翻译：提供包含加替沙星或其药理学上可接受的盐或其水合物，磷酸或其盐和黄原胶的水性液体制剂，其pH为5.5以上且小于7.0。含水液体制剂改善了加替沙星的眼内渗透。此外，通过并入至少一种选自烟酰胺，咖啡因，甲基葡糖胺，对羟基苯甲酸甲酯的成分中的至少一种，可以抑制在较低温度下和在水性液体制剂的冷冻和解冻时储存期间的沉淀物及其盐加入到含水液体制剂中。

23. 发明申请

US20090220580A1 Percutaneous Absorption Formulation 审中-公开
标题翻译：经皮吸收制剂
公开(公告)号：US20090220580A1
公开(公告)日：2009-09-03
申请号：US11918133
申请日：2005-04-20
申请人： Kouji Kawahara , Yasuhiko Aramomi , Noriko Shimada , Akira Ohtori , Akiharu Isowaki
发明人： Kouji Kawahara , Yasuhiko Aramomi , Noriko Shimada , Akira Ohtori , Akiharu Isowaki
IPC分类号： A61K9/70 , A61K31/4535 , A61P11/06 , A61P17/00 , A61P11/00
CPC分类号： A61K31/4535 , A61K9/7053 , A61K9/7076 , A61K47/14
摘要： The present invention provides a percutaneous absorption formulation including a patch having an adhesive layer disposed on a substrate and the adhesive layer contains ketotifen fumarate and tris(hydroxymethyl)aminomethane, and the patch is packaged in a hygroscopic packaging material. In the percutaneous absorption formulation, tris(hydroxymethyl)aminomethane particularly selected from various basic substances is incorporated, and by packaging the patch in a hygroscopic packaging material, the percutaneous absorptivity and content stability of a drug can be simultaneously improved and the yellowing of the drug can be suppressed. These effects can be further improved by the incorporation of propyl gallate, the use of an adhesive layer including an SIS-based adhesive base and a rosin ester-based adhesion imparting resin, and/or the removal of oxygen from the atmosphere in the inside of the packaging material.
摘要翻译：本发明提供一种经皮吸收制剂，其包括具有设置在基底上的粘合剂层的贴剂，并且所述粘合剂层含有富马酸酮替芬和三（羟甲基）氨基甲烷，并且将该贴剂包装在吸湿性包装材料中。在经皮吸收制剂中，加入特别选自各种碱性物质的三（羟甲基）氨基甲烷，通过将吸收包装材料包装在吸湿包装材料中，药物的经皮吸收性和含量稳定性可以同时改善，药物变黄可以抑制。通过加入没食子酸丙酯可以进一步改善这些效果，使用包含基于SIS的粘合剂基质和基于松香酯的粘合赋予树脂的粘合层，和/或从内部的大气中除去氧包装材料。

24. 发明授权

US07572833B2 Drug composition comprising dipeptidyl aldehyde derivative 失效
标题翻译：药物组合物包含二肽基醛衍生物
公开(公告)号：US07572833B2
公开(公告)日：2009-08-11
申请号：US10415295
申请日：2001-09-27
申请人： Jun Inoue , Masazumi Yamaguchi
发明人： Jun Inoue , Masazumi Yamaguchi
IPC分类号： A61K31/18
CPC分类号： A61K47/28 , A61K9/0019 , A61K9/0048 , A61K9/127 , A61K9/4858 , A61K31/18 , A61K31/404 , A61K47/02 , A61K47/24 , A61K47/54
摘要： The present invention provides a preparation containing a compound of the formula (I) wherein R1 is an alkyl group having 1 to 4 carbon atoms or an optionally substituted aryl group having 6 to 10 carbon atoms; R2 and R3 are the same or different and each is hydrogen or an alkyl group having 1 to 4 carbon atoms, or R2 and R3 in combination form a ring having 3 to 7 carbon atoms; and R4 is a lower alkyl group optionally substituted by aryl, cycloalkyl or aromatic heterocyclic residue, or a pharmaceutically acceptable salt thereof together with a lipid. The preparation shows improved stability and improved absorption and penetration into tissue.
摘要翻译：本发明提供含有式（I）的化合物的制备方法，其中R 1为碳原子数为1〜4的烷基或可具有取代基的碳原子数6〜10的芳基。 R2和R3相同或不同，各自为氢或具有1至4个碳原子的烷基，或R2和R3组合形成具有3至7个碳原子的环; 并且R 4是任选被芳基，环烷基或芳族杂环残基或其药学上可接受的盐与脂质取代的低级烷基。该制剂显示改进的稳定性和改善的吸收和渗透到组织中。

25. 发明申请

US20090068744A1 VITREOUS CELL LINE 审中-公开
标题翻译： VITREOUS细胞系
公开(公告)号：US20090068744A1
公开(公告)日：2009-03-12
申请号：US12279432
申请日：2007-02-13
申请人： Hidetoshi Yamashita , Teiko Yamamoto , Kouichi Nishitsuka , Yoshiko Kashiwagi , Naoki Tojo
发明人： Hidetoshi Yamashita , Teiko Yamamoto , Kouichi Nishitsuka , Yoshiko Kashiwagi , Naoki Tojo
IPC分类号： C12N5/10 , C12N15/85
CPC分类号： C12N5/0621 , C12N2501/135 , C12N2501/15 , C12N2501/165 , C12N2501/23 , C12N2501/25 , C12N2501/905 , C12N2503/00 , C12N2503/02 , C12N2510/04
摘要： The present invention provides a vitreous cell line capable of expressing an exogenous immortalizing gene, and a production method thereof. Since the vitreous cell line of the present invention can produce a sufficient number of cells and has constant and continuous proliferative capacity, it can be advantageously utilized for the elucidation of the pathogenesis of retinal vitreous diseases, and the development of a drug for the prophylaxis and/or treatment of retinal vitreous diseases. Moreover, the cell line is not only highly useful for the biochemical-physiological studies of the vitreous body, and further for the study of cell differentiation mechanisms, but also possibly usable as a biological material of an artificial vitreous body.
摘要翻译：本发明提供能够表达外源永生化基因的玻璃体细胞系及其制备方法。由于本发明的玻璃体细胞系可以产生足够数量的细胞并且具有恒定和连续的增殖能力，因此可以有利地用于阐明视网膜玻璃体疾病的发病机理，并且开发用于预防和 /或治疗视网膜玻璃体疾病。此外，细胞系不仅对玻璃体的生物化学生理学研究非常有用，进一步用于研究细胞分化机制，而且还可用作人造玻璃体的生物材料。

26. 发明授权

US07109208B2 Visual function disorder improving agents 有权
标题翻译：视觉功能障碍改善剂
公开(公告)号：US07109208B2
公开(公告)日：2006-09-19
申请号：US10474369
申请日：2002-04-11
申请人： Yoshiko Takayama , Yukuo Yoshida , Masayoshi Uehata
发明人： Yoshiko Takayama , Yukuo Yoshida , Masayoshi Uehata
IPC分类号： A61K31/437 , A61K31/44
CPC分类号： C07D471/04 , A61K9/0048 , A61K31/00 , A61K31/437 , C07D211/00
摘要： The present invention provides a visual function disorder improving agent containing a compound having Rho kinase inhibitory activity, particularly (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide, as an effective component. This agent has axon of the retinal ganglion cellal extension promoting action and optic nerve cell regeneration promoting action, and is useful for the treatment of a visual function disorder associated with various eye diseases caused by damage, defects, degeneration and the like in the retinal or optic nerve.
摘要翻译：本发明提供含有具有Rho激酶抑制活性的化合物的视觉功能障碍改善剂，特别是（R） - （+） - N-（1H-吡咯并[2,3-b]吡啶-4-基）-4- （1-氨基乙基）苯甲酰胺作为有效成分。该药剂具有视网膜神经节细胞延伸促进作用和视神经细胞再生促进作用的轴突，并且可用于治疗由视网膜中的损伤，缺陷，变性等引起的各种眼病的视觉功能障碍，视神经

27. 发明授权

US6057290A Angiogenesis inhibitor 失效
标题翻译：血管生成抑制剂
公开(公告)号：US6057290A
公开(公告)日：2000-05-02
申请号：US740069
申请日：1996-10-24
申请人： Chiho Fukiage , Mitsuyoshi Azuma , Jun Inoue , Masayuki Nakamura , Yuka Yoshida
发明人： Chiho Fukiage , Mitsuyoshi Azuma , Jun Inoue , Masayuki Nakamura , Yuka Yoshida
IPC分类号： A61K38/55 , C07C311/19 , C07D303/48 , A61K38/00 , C07K5/00 , C07K7/00
CPC分类号： A61K38/55 , C07C311/19 , C07D303/48
摘要： An angiogenesis inhibitor comprising a cysteine protease inhibitory compound. As the preferable cysteine protease inhibitory compound, epoxysuccinic acid compounds, peptide halohydrazide compounds, calpain inhibitory compounds, compounds of the formula (I) ##STR1## and compounds of the formula (VI) ##STR2## can be used. The angiogenesis inhibitor of the present invention suppresses new formation of blood vessels in the living tissues, so that it can be used as a superior therapeutic or prophylactic agent of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; and angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, senile discoid macular degeneration and the like, as well as for prevention of metastasis of tumors.
摘要翻译：一种包含半胱氨酸蛋白酶抑制化合物的血管生成抑制剂。作为优选的半胱氨酸蛋白酶抑制化合物，可以使用环氧琥珀酸化合物，肽卤代酰肼化合物，钙蛋白酶抑制化合物，式（I）的化合物和式（VI）的化合物。本发明的血管发生抑制剂抑制活组织中血管的新形成，可以用作与伤口愈合，炎症，肿瘤生长等有关的血管生成的优异治疗或预防剂。和血管生成，如糖尿病视网膜病变，早产儿视网膜病变，视网膜静脉闭塞，老年性盘状黄斑变性等，以及用于预防肿瘤转移。

28. 发明授权

US5994405A Agent for contact lenses 失效
标题翻译：隐形眼镜代理
公开(公告)号：US5994405A
公开(公告)日：1999-11-30
申请号：US10798
申请日：1998-01-22
申请人： Koji Doi , Shuuichi Nishihata , Takuya Nakajima
发明人： Koji Doi , Shuuichi Nishihata , Takuya Nakajima
IPC分类号： A01N37/18 , A61L12/14 , A61K31/16
CPC分类号： A61L12/14 , A01N37/18 , Y10S514/912
摘要： An agent for contact lenses, comprising chloroacetamide. According to the present invention, chloroacetamide, which is the bacteriocidal component to be contained, is scarcely adsorbed not only to hard contact lenses and gas-permeable hard contact lenses, but also to soft contact lenses, and even if adsorbed, moreover, chloroacetamide is quickly released and is not accumulated on the contact lens to a greater extent. The inventive agent containing, in addition to chloroacetamide, sodium lauryl sulfate shows more superior bacteriocidal effect and cleaning effect. Therefore, the present invention provides an agent for contact lenses having superior bacteriocidal effect and cleaning effect, which can be used safely and with ease for various contact lenses inclusive of soft contact lenses.
摘要翻译：隐形眼镜剂，包含氯乙酰胺。根据本发明，作为所含有的杀菌成分的氯乙酰胺不仅难以吸附在硬性隐形眼镜和透气性硬隐形眼镜上，而且也被吸附在软性隐形眼镜上，而且氯乙酰胺是迅速释放并且不会在隐形眼镜上积累更多的程度。含有氯乙酰胺十二烷基硫酸钠的本发明剂具有更优异的杀菌效果和清洁效果。因此，本发明提供了具有优良杀菌效果和清洁效果的隐形眼镜剂，其可以安全地并且容易地用于包括软性隐形眼镜的各种隐形眼镜。

29. 发明授权

US5981530A Piperazine derivative 失效
标题翻译：哌嗪衍生物
公开(公告)号：US5981530A
公开(公告)日：1999-11-09
申请号：US622003
申请日：1996-03-26
申请人： Kazumi Ogata , Takahiro Sakaue , Kazuhiko Ito , Hidetoshi Nakao
发明人： Kazumi Ogata , Takahiro Sakaue , Kazuhiko Ito , Hidetoshi Nakao
IPC分类号： C07D295/155 , A61K31/495 , C07D295/08
CPC分类号： C07D295/155
摘要： The present invention provides a piperazine derivative of the following formula or a pharmacologically acceptable salt thereof ##STR1## wherein R.sub.1 represents a benzene ring, naphthalene ring, quinoline ring, indole ring or chroman ring that may be substituted by lower alkyl, lower alkoxy and/or hydroxy; R.sub.2 and R.sub.3 independently represent hydrogen or lower alkyl.The compound of the present invention has potent antiallergic activity and can therefore be used with advantage in the treatment of various allergic diseases.
摘要翻译：本发明提供下式的哌嗪衍生物或其药理学上可接受的盐，其中R1表示可被低级烷基，低级烷氧基和/或羟基取代的苯环，萘环，喹啉环，吲哚环或苯并二氢吡喃基; R2和R3独立地表示氢或低级烷基。本发明的化合物具有有效的抗过敏活性，因此可有效地用于治疗各种过敏性疾病。

30. 发明授权

US5942487A Composition for treating cornea 失效
标题翻译：用于治疗角膜的组合物
公开(公告)号：US5942487A
公开(公告)日：1999-08-24
申请号：US976088
申请日：1997-11-21
申请人： Takahiro Ogawa , Hideki Tokushige , Noriko Watanabe
发明人： Takahiro Ogawa , Hideki Tokushige , Noriko Watanabe
IPC分类号： A61K38/00 , A61K38/18 , A61K38/21 , A61K38/27 , A61P27/02 , C07K14/52 , A61K31/00
CPC分类号： A61K38/18 , A61K38/19 , A61K38/28 , A61K38/30 , Y10S514/912
摘要： A pharmaceutical composition comprising a stem cell factor (SCF) is administered systemically or locally, preferably administered locally to the eye surface to promote the healing of corneal disorder or injured part in comparison with untreated control.
摘要翻译：包括干细胞因子（SCF）的药物组合物全身或局部施用，优选与眼部表面局部施用以促进角膜障碍或损伤部位的愈合，与未处理的对照相比。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式